Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Inmune Bio (INMB) Depreciation & Amortization (CF) (2025)

Inmune Bio (INMB) has disclosed Depreciation & Amortization (CF) for 1 consecutive years, with $56000.0 as the latest value for Q4 2025.

Quarterly Depreciation & Amortization (CF) changed N/A to $56000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $84000.0 for FY2025, N/A changed from the prior year.
Depreciation & Amortization (CF) hit $56000.0 in Q4 2025 for Inmune Bio.
In the past five years, Depreciation & Amortization (CF) ranged from a high of $56000.0 in Q4 2025 to a low of $56000.0 in Q4 2025.